Physician profile
Brian Brimhall
NPI 1245796101
$5,612.84
in general payments reported to CMS, 2019-2025
19 companies · $1,770 in 2025
The $1,770 reported for 2025 was more than what 90% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $433 · 2022: $618 · 2023: $1,666 · 2024: $1,126 · 2025: $1,770.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,837 · Travel and Lodging: $714 · Education: $11.87.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,836.71 |
| Travel and Lodging | $713.50 |
| Education | $11.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,442.41 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $1,142.92 | 2021-2025 | Spravato, Invega Sustenna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $829.60 | 2021-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $425.04 | 2021-2025 | Fanapt |
| Otsuka America Pharmaceutical, INC. | $304.39 | 2022-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Alkermes, INC. | $266.61 | 2021-2025 | Lybalvi, Aristada, Vivitrol |
| Lundbeck LLC | $224.30 | 2023-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $180.46 | 2025 | |
| Axsome Therapeutics, INC. | $160.08 | 2024-2025 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $157.35 | 2022-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Supernus Pharmaceuticals, INC. | $143.55 | 2021-2025 | Qelbree, Qelbree |
| Indivior INC. | $114.95 | 2021-2025 | Sublocade |
| E.R. Squibb & Sons, L.L.C. | $72.00 | 2024-2025 | Cobenfy |
| Takeda Pharmaceuticals U.S.A., INC. | $56.26 | 2024-2025 | Trintellix, Entyvio |
| Corium, LLC | $29.54 | 2023-2024 | Azstarys |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.19 | 2023 | |
| Idorsia Pharmaceuticals US INC | $20.58 | 2024 | Quviviq |
| Sunovion Pharmaceuticals INC. | $11.90 | 2022 | |
| Phathom Pharmaceuticals, INC. | $9.71 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Brimhall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.